Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

Executive Summary

A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.

You may also be interested in...



Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza

Neurocrine secured FDA approval for the first drug to treat tardive dyskinesia, a large market that crosses multiple diseases and has blockbuster potential.

Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine

The latest drug development news and highlights from our US FDA Performance Tracker.

Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia

Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097345

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel